Zydus Lifesciences Arm to Acquire U.S.-Based Assertio for $166 Mn

The acquisition will be executed through a tender offer followed by a merger, under which Zydus will acquire all outstanding shares of Assertio common stock.

Zydus Lifesciences through its subsidiary Zydus Worldwide DMCC has signed a definitive agreement to acquire U.S.-based Assertio Holdings for $23.50 per share in cash, valuing the transaction at approximately $166.4 million on a fully diluted basis.

The acquisition will be executed through a tender offer followed by a merger, under which Zydus will acquire all outstanding shares of Assertio common stock. The deal will proceed subject to customary closing conditions, including minimum shareholder acceptance representing at least a majority of Assertio’s outstanding shares.

Once the tender offer is completed, Zydus will acquire any remaining shares in a second-step merger at the same price offered in the initial transaction.

Zydus said the acquisition will strengthen its presence in the U.S. specialty and oncology supportive care market by leveraging Assertio’s existing commercial platform.

Assertio’s portfolio includes ROLVEDON (eflapegrastim-xnst), a U.S. FDA-approved biologic used for the prevention of febrile neutropenia in adult cancer patients undergoing myelosuppressive chemotherapy.

The tender offer is expected to begin within five business days from the signing of the merger agreement. The transaction is projected to close in financial year 2026–27, subject to regulatory approvals and completion of all closing requirements.

Zydus Managing Director Sharvil P. Patel said the acquisition aligns with the company’s long-term strategy of expanding its global specialty and oncology footprint, particularly in the United States market.

The deal represents another cross-border expansion move by Indian pharmaceutical companies aiming to strengthen their presence in high-value specialty care segments in developed markets.

Stay tuned for more such updates on Digital Health News